Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD

Chronic lung disease: ‘Triple’ therapy could prove beneficial A dual bronchodilator therapy taken together with corticosteroid inhalers may benefit patients with severe chronic lung disease. Bronchodilator drugs relax the lungs and widen airways in patients with chronic obstructive pulmonary disease...

Full description

Bibliographic Details
Main Authors: Anthony D’Urzo, Dave Singh, Esther Garcia Gil
Format: Article
Language:English
Published: Nature Publishing Group 2017-02-01
Series:npj Primary Care Respiratory Medicine
Online Access:https://doi.org/10.1038/s41533-016-0009-3
Description
Summary:Chronic lung disease: ‘Triple’ therapy could prove beneficial A dual bronchodilator therapy taken together with corticosteroid inhalers may benefit patients with severe chronic lung disease. Bronchodilator drugs relax the lungs and widen airways in patients with chronic obstructive pulmonary disease (COPD). While recent studies have shown that a dual bronchodilator therapy containing aclidinium and formoterol significantly improves lung function in COPD, little is known about combining the dual therapy with inhaled corticosteroids (ICSs). Anthony D’Urzo at the University of Toronto, Canada, and co-workers analysed data from 3394 patients with COPD undergoing dual therapy trials. Of these, 1180 were already taking ICSs. The team compared symptoms in the ICS group with those not taking ICSs. The dual therapy improved lung function across both groups regardless of ICS use, though patients gained different clinical benefits depending on ICS use and disease severity.
ISSN:2055-1010